Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Oncology
Oncology · The big question

Why Glioblastoma Is So Hard to Treat and How Medicine is Adapting

Glioblastoma: epidemiology, molecular pathogenesis, diagnosis, management, and therapeutic resistance.

PubMed2 min readAI-assisted summary
Editorial illustration for Glioblastoma: epidemiology, molecular pathogenesis, diagnosis, management, and therapeutic resistance.
Editorial illustration

Summary

Glioblastoma, or GBM, is the most common and lethal type of primary malignant brain tumor in adults. Even when patients receive the most aggressive standard of care available today, including surgery, radiation, and chemotherapy drugs like temozolomide, the median survival time is only about 15 months. Researchers note that these standard treatments, which also include tumor treating fields, have reached a therapeutic plateau. This means they are no longer yielding significant improvements in patient survival, highlighting a desperate need for a new approach.

Recently, doctors have become much better at diagnosing the disease by looking closely at its genetic and molecular makeup. In 2021, the World Health Organization updated its diagnostic guidelines to classify these tumors based on specific cellular features, such as missing tumor suppressors like PTEN or amplified genes like EGFR. However, this diagnostic precision has not yet unlocked new cures. Even immunotherapy, a treatment designed to help the immune system fight off disease, currently offers limited benefits for glioblastoma. This is partly because the brain is protected by a strict biological shield called the blood-brain barrier. Furthermore, these tumors display a low number of overall mutations, making them much harder for the body's natural defenses to detect.

The biggest hurdle of all is the tumor's profound spatial and temporal heterogeneity. In simple terms, this means the cancer is incredibly diverse and constantly evolving. Different regions of the same tumor have entirely different traits, and these traits shift over time. Because the cancer is always changing, it easily evades modern therapies. It is worth noting that this paper is a comprehensive review, meaning the authors synthesized existing scientific literature on these resistance mechanisms rather than presenting new experimental data. By mapping out exactly how these tumors hide, they hope to inspire new ways to fight back.

Why it matters.

Understanding the exact reasons why glioblastoma evades treatment is a crucial first step toward developing better therapies. For the adult patients diagnosed with this aggressive cancer, the current 15-month median survival rate is a stark reminder that traditional medical approaches have maxed out their effectiveness. The future of brain cancer treatment relies entirely on outsmarting the tumor's constant evolution and finding ways to breach the biological defenses of the brain.

By synthesizing all the known ways these tumors resist treatment, researchers can pivot toward more advanced, dynamic strategies. Future treatments will likely require a highly customized approach, combining targeted drug delivery systems that bypass the blood-brain barrier with adaptive therapies that can shift just as quickly as the cancer does. While this review does not offer an immediate cure, it provides a vital blueprint for the next generation of clinical trials and pharmaceutical development.

From the source

The story in numbers.

Median survival
15 months
WHO classification year
2021
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Oncology

Targeted Drug Spares Lymphoma Patients from Stem Cell Transplants

Mantle cell lymphoma is a challenging type of blood cancer. For years, the standard treatment for younger, relatively fit patients has been a heavy dose of chemotherapy followed by an autologous stem cell transplant. This transplant process involves collecting a patient's own healthy stem cells, delivering high-dose chemotherapy to wipe out the cancer, and then returning the healthy cells to help the body recover. It is an intense procedure that can be incredibly hard on the body. A recent major clinical trial followed 870 patients across Europe and Israel for over four years to see if adding a targeted daily pill called ibrutinib could improve outcomes. Researchers split the patients into three groups to test different combinations of standard chemotherapy, ibrutinib, and stem cell transplants. They found that adding ibrutinib significantly boosted both how long patients lived overall and how long they lived without their cancer returning or worsening. The most welcome discovery was that the grueling stem cell transplant may no longer be necessary. The group that received chemotherapy and ibrutinib but skipped the transplant did just as well as the group that received all three. Adding the transplant to the ibrutinib regimen provided no extra survival benefit but significantly increased the risk of severe side effects, like dangerous drops in healthy blood cells. It is worth noting that this study only looked at untreated patients aged 18 to 65, so the findings might not apply to older or less fit individuals.

PubMed2 min read
Oncology

Colorectal Cancer Prepares to Spread Earlier Than We Thought

For anyone diagnosed with cancer, the most dangerous moment is when the disease begins to spread to new areas of the body, a process known as metastasis. Scientists have long wondered exactly when and how a localized tumor gains the ability to travel. In a new study looking at colorectal cancer, researchers made a surprising discovery. They found that tumors actually develop the necessary tools to spread much earlier than previously believed. By studying patient samples and miniature lab-grown tumors called organoids, the research team looked at how tumor cells behave at a microscopic level. They discovered that many early-stage tumors adopt a highly flexible condition called an oncofetal state. Normally, this shapeshifting ability is only seen in advanced, late-stage cancers. But the researchers found that these flexible cancer cells were already gathering at the edges of early tumors. There, they mingle with normal connective tissue cells known as fibroblasts, which actively encourage the cancer cells to become even more adaptable and ready to move. However, simply having these flexible cells is not enough to guarantee the cancer will spread, since not all early-stage tumors actually go on to metastasize. The researchers investigated what pushes the tumor over the edge. They ruled out new genetic mutations as the trigger. Instead, their findings suggest that a cancer cell's ability to hide from the immune system might be the final key to unlocking its deadly spread.

Nature Genetics2 min read
Oncology

New nanoparticle tech breaks down tumor shields to boost immunity

Tumors have a sneaky way of hiding from the body's immune system. They wrap themselves in a dense, sugary protective coating known as the glycocalyx. This shield is packed with mucins, which are thick proteins that physically block immune cells and modern cancer treatments from reaching the target. While scientists have discovered a bacterial enzyme called StcE that can chew through this sticky barrier, using it as a drug has been difficult. Injecting the free enzyme directly into the body causes unwanted toxic side effects and triggers severe immune reactions. To solve this problem, researchers engineered a clever delivery system using cell membrane fusion nanovesicles, which are essentially microscopic bubbles made from natural cell materials. They equipped these tiny delivery vehicles with both the barrier-breaking StcE enzyme and specialized targeting molecules called CD47 nanobodies. These nanobodies act like a homing device that seeks out cancer cells. By using this biomimetic delivery platform, the enzyme successfully digests the protective sugary shield precisely at the tumor site, avoiding the widespread toxicity and safety issues of the free enzyme. With the barrier cleared away, the immune system gets a much clearer shot at the tumor. The researchers found that removing the mucin shield allowed the nanobodies to bind tightly to the cancer cells, sounding the alarm for the body's natural defenses. The treatment successfully suppressed tumor growth and stopped the cancer from spreading by radically remodeling the environment around the tumor, bringing in a flood of protective immune cells.

PubMed2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
Why Glioblastoma Is So Hard to Treat and How Medicine is Adapting — Daily Strand